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ABSTRACT 
Objective: The objective of this selective EBM review is to determine whether or not 
Rimonabant is a safe and effective treatment for patients with alcohol dependence. 
Study Design: Systematic review of three English language randomized control trials published 
in 2005, 2008 and 2010.  
Data Sources: Three double-blind, placebo controlled randomized trials comparing Rimonabant 
or Naltrexone to placebo were found using PubMed, OVID, Medline and Cochrane.  
Outcomes Measured: Outcomes measured include event rate of heavy drinking days using the 
timeline follow back method, which facilitates self-reporting of drinking habits by utilizing 
calendars and personal recall. Other outcomes measured include the number of self-reported 
drinks/day using daily call ins from study participants and number of days until first alcoholic 
drink and number of days until first heavy drinking (as measured by timeline follow back 
method). 
 Results: In a study by George et.al, there was no significant difference found in the number of 
alcoholic drinks consumed by non-treatment seeking heavy alcohol drinkers when comparing the 
Rimonabant and placebo groups during the 14 day study. A study by Soyka et.al. discovered that 
participants treated with once daily Rimonabant showed a marked, but not statistically 
significant, reduction in relapse to heavy drinking when compared to placebo after 12 weeks oif 
treatment: 27.7% versus 35.6%, respectfully. Finally, another study included in this review 
investigated the efficacy of intramuscular naltrexone as a treatment for alcohol dependence by 
measuring the event rate of heavy drinking days. Results of this study showed that long-acting 
IM naltrexone resulted in 25% reduction in heavy drinking days among treatment-seeking 
alcohol dependent patients when compared to placebo. The compiled data also demonstrates that 
both Rimonabant and Naltrexone are relatively safe to use in adult alcoholics, however patients 
receiving Rimonabant were more likely to have treatment emergent adverse events such as 
nausea, insomnia, headache, etc.  
Conclusions: The results of two double-blind placebo controlled randomized control trials 
showed no statistical treatment effect of Rimonabant versus placebo in reducing the number of 
drinks per day, number of heavy drinking days, or time to heavy drinking relapse. Both 
Naltrexone and Rimonabant are considered safe for use in adults, despite a modest amount of  
mild adverse reactions associated with treatment.  
Key Words: Rimonabant, Naltrexone, Alcohol dependence 
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INTRODUCTION 
 Alcohol dependence is a serious medical health problem in the U.S., and has recently 
become the 4th leading cause of disability in America5. Alcohol dependence, also known as 
alcoholism, is a syndrome consisting of two phases: at risk drinking and alcohol addiction. At 
risk drinking is typically defined as more than 4 drinks per day or 14 drinks per week for men 
and more than 3 drinks per day or 7 drinks per week for women4. People affected by alcoholism 
often show evidence of withdrawal when intake is interrupted, tolerance to the effects of alcohol, 
and evidence of alcohol-associated illnesses such and alcoholic liver disease and cerebellar 
degeneration10.  
 The lifetime risk for alcohol dependence in Western countries is 10-15% for men and 5-
8% for women10. Alcoholism may contribute to more than 80,000 preventable deaths per year 
and is responsible for 2.3 million years of potential life lost annually1. About 80% of people in 
Western countries have consumed ethanol, and two-thirds admit to being drunk in the past year, 
demonstrating how large of a demographic is at risk for alcoholism10. With this knowledge, it is 
imperative for the physician assistant to have a low threshold of suspicion for alcohol abuse or 
dependency in any person with a history of drug or alcohol consumption or clinical 
manifestations of acute or chronic intoxication. 
 In 2006, the overall cost to the United States for alcohol-related health problems was 
estimated to be $223.5 billion1. In 2006, there were more than 1.2 million emergency room visits 
and more than 2.7 million physician office visits for alcohol-related conditions1. Life span is 
decreased by 10 years in an alcoholic, with death most commonly resulting from heart disease, 
cancer, automobile accidents and suicide10.  
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 Alcohol dependence is a chronic disease that typically presents with a craving for alcohol 
and the inability to limit one’s intake of alcoholonitnued use of alcohol despite negative social, 
physical and interpersonal problems or developmental of alcohol-related illnesses4. Potential 
health complications of alcoholism include cardiomyopathy, cerebellar degeneration, peripheral 
neuropathies, cirrhosis of the liver, esophageal varices, hormonal and nutritional deficiencies, 
coagulation defects, pancreatitis, depression, psychological disease, cancer and fetal alcohol 
syndrome in babies of alcoholic mothers4,10. Acute alcohol intoxication produces CNS 
depression, manifesting as drowsiness, psychomotor dysfunction, lack of inhibition, dysarthria, 
ataxia and nystagmus. Blood alcohol levels below 50 mg/dL rarely cause significant motor 
dysfunction, while alcohol ingestion coupled with nausea and vomiting suggest blood alcohol 
levels > 150 mg/dL4.  
 Alcohol dependence is diagnosed clinically by the DSM-IV as repeated alcohol related 
difficulties in at least three of seven life areas over a 12 month period. Tolerance and withdrawal 
symptoms are associated with more severe dependence. Some lab values may aid in the 
diagnosis, including elevated liver enzymes, GTT> 35U, CDT > 20 U/L, high MCV (>91 um3) 
and high serum uric acid (>416 mol/L)10. Questionnaires and interviewing methods such as the 
CAGE questions and the AUDIT (The Alcohol Use Disorders Test) are a valuable tool for 
identifying those patients with alcohol abuse or dependence4. 
 Cognitive behavioral therapy with an emphasis on motivational interviewing is the 
primary intervention for alcoholism. Goals of CBT include emphasizing the positive actions that 
the patient can take to reduce their alcohol consumption, reducing any “enabling” behavior of a 
spouse or significant people, and facing denial. Rehabilitation, counseling and self-help groups 
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such as Alcoholics Anonymous are an integral component of successful treatment. After 
completing rehabilitation and CBT, over 60% of alcoholics remain sober for at least 1 year10. 
 Medical therapies are available for the treatment of alcoholism and include Disulfiram, 
Acamprosate, and Naltrexone.  Disulfiram, an ALDH inhibitor, produces symptoms of nausea 
and vomiting with rising levels of acetaldehyde (breakdown product of ethanol) in the blood10. 
This reaction may be dangerous for patients with heart disease, DM or stroke. Acamprosate has 
modest effects on alcohol intake and functions by inhibiting NMDA receptors, resulting in a 
decrease in the pleasurable side effects of ethanol ingestion. Naltrexone, an opioid receptor 
antagonist, appears to shorten relapses, especially in patients with a specific mu-receptor 
polymorphism4,10. Studies have suggested that use of Acamoprosate and Naltrexone in 
combination is more efficacious than use alone10.  
 The CB1 cannabinoid receptor and mu-opioid receptors have been shown to have a 
similar distribution in the brain, specifically sharing the same pre-synaptic nerve terminals and 
signaling through a common receptor mediated G-protein coupled pathway7. Naltrexone, a mu 
receptor blocker, is currently the first-line medical therapy for alcohol dependence. Animal 
studies have shown that CB1 knockout mice had reduced voluntary alcohol consumption and 
increased alcohol sensitivity2. Based on the success of Naltrexone combined with the positive 
treatment response in animal studies, there is sufficient data to suggest that a CB1 cannabinoid 
receptor antagonist such as Rimonabant may have a similarly therapeutic response in treating 
alcoholism.  
OBJECTIVE 
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The objective of this selective EBM review is to determine whether or not Rimonabant 
(Acomplia) is a safe and effective treatment for patients with alcohol dependence. 
METHODS 
 Specific selection of three double-blind, placebo controlled randomized control trials 
(RCT) were used for this review. The chosen population included adults > 18 years old with a 
diagnosis of alcohol dependence or abuse. Interventions studied included Rimonabant 20 mg PO 
QD and Naltrexone 380 mg IM and 190 mg IM. Comparisons were made between treatment 
groups receiving Rimonabant or Naltrexone versus a placebo. Outcomes measures include event 
rate of heavy drinking (>5 standard drinks/day for men, >4 standard drinks/day for women), 
number of drinks per day, time to drinking and time to heavy drinking relapse (in days). All 
outcomes were measured using patient self-reporting via call-ins or the timeline follow-back 
method (based on calendars and personal recall). Safety associated and tolerability of 
Rimonabant and Naltrexone were measured on the basis of adverse events (AE) and serious 
adverse events (SAE). 
 Over the time period of November 2011-January 2012 the author accessed PubMed, 
Medline, OVID and Cochrane Systemic Reviews using the key words “Rimonabant”, “Alcohol 
dependence”, “alcohol” and “Naltrexone” to search for relevant RCTs. While searching for 
articles inclusion criteria included: English language, human adult participants, articles published 
within the past 10 years, peer-reviewed journals, randomized control trials and relevance to my 
clinical question. All outcomes investigated are based on outcomes that are important to patients 
(POEMs). Exclusion criteria can be found in Table 1. The statistics included in the data analysis 
include NNT, NNH, p-values, hazard ratios and F-score. 
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Table 1- Demographics and Characteristics of Included Studies 
Study Type # pts Age Inclusion Criteria Exclusion Criteria W/D Interventions  
Garbutt 
(2005)5 
Double 
Blind 
RCT 
624 45 ± 10 
years  
>18 y/o with 
current DSM-
IVdiagnosis of 
alcohol dependence 
with a minimum of 
2 episodes of heavy 
drinking in 30 days 
prior to study 
Evidence of liver 
failure, current 
diagnosis major 
psychiatric illness, 
dependence on 
drugs, previous 
inpatient treatment 
for substance abuse 
3* Naltrexone 
380 mg or 190 
mg IM gluteal 
injection q 4 
weeks x 24 
weeks  
George  
(2010)6 
Double 
Blind 
RCT 
39 32 ± 2 
years 
Age 21-45 who 
consumed 20-50 
drinks/week with a 
BMI of 18-30, 
taking no other 
medications and 
tested negative for 
HIV and hepatitis 
with normal 12-
lead EKG 
 
Major psychiatric 
illness, history of 
withdrawal 
symptoms, not 
currently seeking 
treatment for 
alcohol 
consumption 
0 20 mg of 
Rimonabant 
PO QD x 14 
days 
Soyka  
(2008)11 
Double 
Blind 
RCT 
253 44.8 ± 
8.8 years 
Age 18-65 with 
DSM –IV 
diagnosis of 
alcohol dependence 
who are detoxified 
from alcohol for 7-
28 days prior to 
randomization 
without withdrawal 
symptoms 
Symptoms of 
alcohol withdrawal 
or drinking alcohol 
in 3 days prior to 
study. History of 
WK syndrome, 
withdrawal 
seizures, delirium, 
cirrhosis, or 
alcohol-induced 
psychosis. Pending 
legal charges, IQ < 
80, major 
psychiatric illness 
80 20 mg of 
Rimonabant 
PO QD x 12 
weeks  
*Although 246 participants dropped out of this trial, all patients who received at least 1 injection 
of the long acting naltrexone were included in the final data analysis (624 people).  
OUTCOMES MEASURED 
 The outcomes measured were based on actual patient self-reports. Event rate of heavy 
drinking was measured by taking the number of heavy drinking days divided by the number of 
days at risk for heavy drinking. Heavy drinking is considered to be intake of > 5 standardized 
drinks/day for men or > 4 standardized drinks/day for women5.  Another outcome measured the 
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amount of daily alcoholic beverages consumed by daily patient call in, in an effort to capture the 
patient’s consumption in their natural home setting6. The last outcomes were measured by 
quantifying the number of days before a patient relapsed (based on reported drinking status, 
Timeline Followback report of alcohol consumption, ethanol breath testing, plasma GGT level 
and CDT value). The time until relapse to first period of heavy drinking was also investigated11. 
Drinking status was assessed using the Timeline Followback method and the OCDS (Obsessive 
Compulsive Drinking Scale) at every visit.  
RESULTS 
 Two of the randomized control trials in this systematic review compared treatment with 
oral Rimonabant to placebo, while another RCT compared treatment with intramuscular long-
acting Naltrexone to intramuscular placebo of the same volume.  
The article by Soyka et.al was a 12 week study assessing the efficacy of Rimonabant 20 
mg/day given in two 10 mg oral doses in the prevention of relapse to alcohol consumption in 
recently detoxified alcoholics. Of the 260 patients who began the study, only 71.8% of the 
participants in the Rimonabant group completed therapy while only 62% of participants in the 
placebo group completed therapy11. All dropout patients were considered to have relapsed using 
the Fischer exact test in one of the sensitivity analyses. The primary outcomes of this study 
included time to relapse and time to heavy drinking relapse. The time to relapse of drinking and 
heavy drinking (in days) was increased in the group receiving Rimonabant when compared to 
placebo, however no statistically significant difference was found between the treatment groups. 
The number needed to treat (NNT) value for relapse to heavy drinking in this study is 10, 
meaning that ten patients would need to be treated with Rimonabant to prevent one patient from 
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relapsing to heavy drinking. The p-values are not significant (see Table 3), and the odds ratio is 
very close to 1 in both drinking relapse and heavy drinking relapse, showing that the treatment 
effect was small. Patients taking placebo relapsed to heavy drinking 22 days before patients 
taking Rimonabant. 
Table 2. Primary Outcomes: Time to Relapse and Relapse Rates11 
  Placebo (n=124) Rimonabant 20 mg (n=129) 
Drinking Non-relapse Patients 50 (40.3%) 60 (46.5%) 
Relapse Patients 57 (46.0%) 53 (41.1%) 
Time to Relapse 24 days 33 days 
Heavy 
Drinking 
Non-relapse Patients 58 (47.2%) 71 (57.7%) 
Relapse Patients 40 (32.5%) 32 (26.0%) 
Time to Relapse 52 days 74 days 
Table 3. Calculations for efficacy of relapse prevention11 
 Relative Risk 
Reduction 
(RRR) 
Absolute Risk 
Reduction 
(ARR) 
Number Needed 
to Treat (NNT) 
Odds Ratio P-value 
(< 0.05 is 
significant) 
Relapse to 
Drinking 
15% 6% 16 0.77 0.375 
Relapse to Heavy 
Drinking 
22% 11% 10 0.65 0.125 
 The study by George, et. al. was a 2 week double-blind study with 49 non-treatment 
seeking adult heavy alcohol drinkers who were randomly given either oral Rimonabant 20 
mg/day or placebo. The data showed that there was no significant treatment effect between the 
Rimonabant and placebo groups. The data uncovered in this study is represented in a continuous 
manner and could not be converted to dichotomous data; there for RRR, ARR and NNT cannot 
be calculated. The treatment effect (number of drinks/day) is described by an F-score of F(1,36)= 
0.05 and a p-value of p=0.836. Based on these values, the author determined that the treatment 
effect was small and of no statistical significance. 
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 The study by Garbutt, et al. was a 6-month, randomized, double-blind placebo controlled 
trial investigating the event rate of heavy drinking days after treatment with long-acting 
intramuscular Naltrexone versus placebo in 627 actively alcohol-dependent adults. Although 
only 378 participants actually finished the 6-month trial, all patients who received at least 1 
injection of Naltrexone were included in the final data analysis (624 participants)5. The data 
showed that participants taking 380 mg IM naltrexone had a 25% reduction in the event rate of 
heavy drinking when compared to placebo (p=0.03)5. This p-value is <0.05, showing that there 
was a statistically significant decrease in the rate of heavy drinking days between the treatment 
groups. Male patients and patients without lead in drinking taking Rimonabant had an even more 
significant reduction in the rate of heavy drinking, 44% and 80% respectively. Since the data is 
represented in hazard ratios and no specific data points are given, data is continuous and ABI, 
RBI and NNT cannot be calculated.  
Table 4. Analysis of Outcomes for article by Garbutt et.al.  
  Naltrexone 380 mg v. Placebo Naltrexone 190 mg v Placebo 
 Population Hazard Ratio* P-value Hazard Ratio P-value 
Heavy 
Drinking 
624 0.75 (0.60-0.94) 0.03 0.83 (0.68-1.02) 0.07 
     Female 201 1.23 (0.85-1.78) 0.28 1.07 (0.73-1.58) 0.72 
     Male 423 0.56 (0.41-0.77) <0.001 0.83 (0.64-1.07) 0.16 
Lead in                   
drinking 
571 0.79 (0.62-1.00) 0.05 0.93 (0.75-1.12) 0.48 
    No lead in    
drinking 
53 0.20 (0.07-0.62) 0.005 0.05 (0.02-0.15)  <0.001 
*Hazard ratio is an estimate of treatment effect size for each individual treatment relative to placebo and should be 
interpreted as follow: HR = 1 indicates no treatment effect, HR = 0.75 is  a 25% reduction in heavy drinking relative 
to placebo, HR = 1.25 is a 25% increase in heavy drinking relative to placebo, etc.  
 
SAFETY 
Based on data compiled by Soyka et al, Rimonabant 20 mg/day resulted in a NNH of 23, 
meaning that 23 patients must be treated for one patient to experience a treatment emergent 
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adverse event. NNH for serious adverse events was -38, meaning that thirty eight people would 
have to be treated with Rimonabant for one less serious adverse event to occur versus placebo.  
Of note, three suicide attempts occurred in the placebo group compared to 1 attempted suicide in 
the Rimonabant group. No deaths occurred during the study period.  
Garbutt and colleagues found that 7.2% of patients in the placebo group discontinued 
therapy secondary to a serious adverse event compared to 5.4% of patients in the Naltrexone 380 
mg group. The participants treated with Naltrexone were two times as likely to have an adverse 
event compared to those taking placebo. For every 14 people treated with Naltrexone 380 mg IM 
one more patient experienced an adverse treatment reaction. As for serious adverse events such 
as hospitalization or pneumonia, 55 patients would need to be treated with Naltrexone 380 mg 
IM to experience one less serious adverse event when compared to placebo.  
The study by George et al cited no specific adverse drug reactions, however the author 
states that no significant differences for drug side effects were found using a Visual Analog 
Scale to monitor patients at every clinical visit. No participants reported feelings of depression of 
suicidal ideation.  
Table 5. Safety and tolerability of Rimonabant and Naltrexone  
 Medication 
regimen of 
interest 
Most common adverse side 
affects 
Placebo 
(%) 
Treatment 
(%) 
Number 
needed to 
harm 
(NNH) 
Soyka, 
et.al.11 
Rimonabant 20 
mg/day  
Serious adverse events: 
hospitalization due to 
alcoholism and suicide 
attempts. 
11.8% 9.2% -38 
 
Treatment Emergent 
Adverse Events: 
Headache, Alcoholism, 
Diarrhea, Fatigue, Nausea, 
Insomnia, Anxiety, 
Hypertension, Asthenia, 
48.8% 53.3% 23 
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Depression 
George, 
et.al.6 
Rimonabant 20 
mg/day 
No adverse reactions reported N/A N/A N/A 
Garbutt, 
et.al.5 
Naltrexone 380 mg 
IM 
injection/month 
SAE: Hospitalization for 
alcohol detoxification, 
pneumonia 
7.2% 5.4% -55 
AE: Nausea, headache, 
fatigue, insomnia, vomiting, 
decreased appetite, diarrhea 
6.7% 14.1% 14 
 
DISCUSSION 
 The endocannabinoid and opioid neural signaling pathways have both been implicated in 
the development and maintenance of alcohol dependence and abuse disorders. The opioid 
signaling pathways have already been utilized clinically with the introduction of Naltrexone, an 
opioid mu-receptor antagonist which has been FDA approved for the treatment of alcohol 
dependence. Rimonabant, a CB1 endocannabinoid receptor antagonist, acts on a pathway with a 
very similar mechanism of action in the brain as the opioid signaling pathways7, leading clinical 
scientists to investigate the efficacy of Rimonabant as a treatment for alcohol dependence, based 
on the relative success of Naltrexone. Although animal studies were encouraging and showed a 
significant positive treatment effect with Rimonabant2, the human RCTs discussed in this 
systematic review show no significant treatment effect between Rimonabant and placebo. 
Although Soyka et al found a 11% absolute risk reduction of heavy drinking in participants 
taking Rimonabant, these results were not found to be significant. 
 Limitations to this systematic review were numerous. The study by George et al 
investigated a very small population size (n=49) and treated the participants for a duration of 
only two weeks6. Of the two studies investigating Rimonabant vs. placebo, the treatment groups 
varied significantly: one population included recently detoxified alcohol dependent patients 
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while the other included non-treatment seeking alcoholics. The obvious contrast in the 
population’s willingness and initiative to obtain treatment for alcoholism may substantially 
confound the medication treatment effects.  
Only two placebo-controlled randomized control trials are currently in circulation 
investigating the use of Rimonabant for the treatment of alcohol abuse disorders in humans. 
Reasons for the lack of RCTs may include the numerous treatment options that are already 
available for alcohol dependence, the serious side effects discovered from administration of 
Rimonabant in 2007 by the FDA, including increased risk of suicidal ideation (OR=1.9)3 and 
severe depression (OR=2.5)3, and the lack of FDA approval for the drug Rimonabant. For these 
reasons, coupled with the lack of significant treatment effect found in two randomized control 
trials by Soyka and George, the author believes that future research into this therapeutic option 
should be limited until a more thorough investigation into the drug safety has been concluded 
and FDA approval has been obtained.  
CONCLUSIONS 
 Rimonabant (Acomplia) is a safe treatment for alcohol dependence based on the 
information reported in this systematic review. However, based on previous reports of suicidal 
ideation and severe depression in patients taking Rimonabant, the safety profile for this drug 
requires serious consideration and further study. Effectiveness as evidenced by increased days to 
first relapse and reduced risk of relapse to drinking and heavy drinking were seen, however no 
statistically significant differences were found when comparing treatment with Rimonabant to 
placebo. Future research is warranted to evaluate treatment with a peripherally acting neutral 
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CB1 antagonist8 in a sufficiently large population of alcohol dependent adults who are seeking 
treatment and have already begun cognitive behavioral therapy. 
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